Drug profile · INN
epoetin beta
NEORECORMON
epoetin beta (NEORECORMON) is a erythropoietin receptor agonist. Associated with Hoffmann-La Roche.
EMA: approved TGA: approved Blood and blood forming organs (B03) B03XA01
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — epoetin beta
- Class
- Blood and blood forming organs (B03)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
epoetin beta (NEORECORMON) is a erythropoietin receptor agonist. Associated with Hoffmann-La Roche.
Key facts
INN epoetin beta
Brand NEORECORMON
Mechanism Erythropoietin receptor agonist
Target Erythropoietin receptor
Therapeutic class Blood and blood forming organs (B03)
ATC code B03XA01
Originator Hoffmann-La Roche
Mechanism of action
Erythropoietin receptor agonist
Primary target: Erythropoietin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is epoetin beta?
epoetin beta (NEORECORMON) is a erythropoietin receptor agonist. Associated with Hoffmann-La Roche.
What is the brand name for epoetin beta?
NEORECORMON is a marketed brand name for epoetin beta. Check FDA Drugs@FDA for the current US label holder and prescribing information.